Case report: Pemigatinib-induced retinopathy: a serial examination of subretinal fluid secondary to an FGFR inhibitor

Case report: Pemigatinib-induced retinopathy: a serial examination of subretinal fluid secondary to an FGFR inhibitor

BackgroundModern chemotherapeutic agents continue to evolve as modern monoclonal antibody treatments are designed to directly target proteins, enzymes, and focal loci. A particular class of these medications, fibroblast growth factor (FGFR) inhibitors, specifically pemigatinib (Pemazyre®; Incyte), h...

Full description

Bibliographic Details
Main Authors:	Daniel Barmas-Alamdari, George Jiao, Ronni Lieberman
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-01-01
Series:	Frontiers in Ophthalmology
Subjects:	pemigatinib subretinal fluid FGFR (fibroblast growth factor receptor) FGFR inhibitor pigment epithelial detachment Pemazyre
Online Access:	https://www.frontiersin.org/articles/10.3389/fopht.2023.1247296/full

Similar Items

Multifocal serous retinopathy with pemigatinib therapy for metastatic colon adenocarcinoma
by: Oleg Alekseev, et al.
Published: (2021-04-01)

Clinical experience with pemigatinib for previously treated metastatic cholangiocarcinoma: practical considerations from clinical cases
by: Jonathan Wadsley, et al.
Published: (2023-08-01)

Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study
by: Guo‐Ming Shi, et al.
Published: (2023-02-01)

Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs
by: Angelica Pace, et al.
Published: (2023-09-01)

Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
by: Alessandro Rizzo
Published: (2021-05-01)

Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress
by: Gennaro Gadaleta-Caldarola, et al.
Published: (2022-10-01)

Precision Medicine Targeting FGFR2 Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future Perspectives
by: Miguel Zugman, et al.
Published: (2022-04-01)

FIGHT‐102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies
by: Yutaka Fujiwara, et al.
Published: (2023-05-01)

Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma
by: Zhuochao Zhang, et al.
Published: (2023-05-01)

Successful Long-term Treatment with Modified Dose Pemigatinib in FGFR2-BICC1 Intrahepatic Cholangiocarcinoma: A Case Report
by: Kuan-Chang Lai, et al.
Published: (2024-09-01)

Characterization of FGFR signaling pathway as therapeutic targets for sarcoma patients
by: Wen-Ya Zhou, et al.
Published: (2016-06-01)

Oncogenic FGFR Fusions Produce Centrosome and Cilia Defects by Ectopic Signaling
by: Alexandru Nita, et al.
Published: (2021-06-01)

Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test
by: Shun Ishido, et al.
Published: (2023-07-01)

Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs
by: Maria-Magdalena Georgescu, et al.
Published: (2021-04-01)

A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality
by: Jain Nem Kumar, et al.
Published: (2024-03-01)

Trichiasis and dry eye syndrome in two patients on novel fibroblast growth factor receptor inhibitor therapies
by: Kyle B. Vinson, et al.
Published: (2020-09-01)

Genetic variants of FGFR family associated with height, hypertension, and osteoporosis
by: Hye-Won Cho, et al.
Published: (2023-01-01)

FGFR3–TACC3: A novel gene fusion in cervical cancer
by: Benedito A. Carneiro, et al.
Published: (2015-08-01)

Recent Advances in Tumor Therapy Targeting FGFR
by: ZHANG Jing, et al.
Published: (2022-02-01)

The 8p11 myeloproliferative syndrome: Genotypic and phenotypic classification and targeted therapy
by: Taotao Li, et al.
Published: (2022-11-01)

Recombinant expression in E. coli of human FGFR2 with its transmembrane and extracellular domains
by: Adam Bajinting, et al.
Published: (2017-06-01)

FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?
by: Csongor G. Lengyel, et al.
Published: (2022-01-01)

Persistent response to combination therapy of pemigatinib and chemotherapy in a child of combined hepatocellular-cholangiocarcinoma with FGFR2 fusion
by: Guo-qian He, et al.
Published: (2024-12-01)

Dual activating FGFR1 mutations in pediatric pilomyxoid astrocytoma
by: Elena I. Fomchenko, et al.
Published: (2021-02-01)

Favorable Outcomes in FGFR Fusion-Positive Cholangiocarcinomas and Evolution on Treatment Noted on Circulating Tumor DNA Liquid Biopsies
by: Pashtoon Murtaza Kasi
Published: (2020-08-01)

Therapies targeting triple-negative breast cancer: a perspective on anti-FGFR
by: Jinhao Chen, et al.
Published: (2025-03-01)

Computational Simulation Studies on the Binding Selectivity of 1-(1H-Benzimidazol-5-yl)-5-aminopyrazoles in Complexes with FGFR1 and FGFR4
by: You-Lu Pan, et al.
Published: (2018-03-01)

FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1
by: Silvana Mouron, et al.
Published: (2021-02-01)

Coexisting FGFR3 p.K650T mutation in two FGFR3-TACC3 fusion glioma cases
by: Leomar Y. Ballester, et al.
Published: (2019-04-01)

Progress on the Study of Targeting FGFR in Squamous Non-small Cell Lung Cancer
by: Ming DONG, et al.
Published: (2018-02-01)

FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies
by: Maxim Noeraparast, et al.
Published: (2024-10-01)

Emerging Roles of Fibroblast Growth Factor 10 in Cancer
by: Natasha S. Clayton, et al.
Published: (2018-10-01)

Role of PKCε in the epithelial-mesenchymal transition induced by FGFR2 isoform switch
by: Danilo Ranieri, et al.
Published: (2020-05-01)

Patient Selection Approaches in FGFR Inhibitor Trials—Many Paths to the Same End?
by: Peter Ellinghaus, et al.
Published: (2022-10-01)

FGFR3 promotes the growth and malignancy of melanoma by influencing EMT and the phosphorylation of ERK, AKT, and EGFR
by: Lei Li, et al.
Published: (2019-10-01)

A novel FGFR1 inhibitor CYY292 suppresses tumor progression, invasion, and metastasis of glioblastoma by inhibiting the Akt/GSK3β/snail signaling axis
by: Yanran Bi, et al.
Published: (2024-01-01)

FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer
by: Ying Yang, et al.
Published: (2020-01-01)

Deciphering the FGFR2 Code: Innovative Targets in Gastric Cancer Therapy
by: Alireza Tojjari, et al.
Published: (2024-07-01)

Design, synthesis and biological evaluation of novel 1H-1,2,4-triazole, benzothiazole and indazole-based derivatives as potent FGFR1 inhibitors viafragment-based virtual screening
by: Jian Liu, et al.
Published: (2020-01-01)

Ligand bias underlies differential signaling of multiple FGFs via FGFR1
by: Kelly Karl, et al.
Published: (2024-04-01)